Exploring New Investigational Topical Treatment for Moderate Eczema

Trial Objectives

While there are a variety of treatments currently available for eczema, including topical steroids, the current treatments do not work for all children. As part of the TRuE-AD 5 study, researchers are testing a potential new, non-steroid topical cream called ruxolitinib. The goal is to determine if ruxolitinib is safe and effective for treating moderate eczema in children and teens ages 6-17 whose eczema does not respond to other topical treatments. Ruxolitinib works by blocking inflammatory enzymes called Janus kinases (JAKs), which may help reduce redness, itching and other symptoms.

Volunteers in this study will be randomly assigned to receive either ruxolitinib or a cream that does not contain the study medication. They will apply the cream twice a day for 8 weeks. If their symptoms do not improve within 8 weeks, they can move into a second phase of the study where all volunteers will receive ruxolitinib for 8 more weeks. If their symptoms respond during this time, they can continue to use the cream for the remaining study period.

During clinic visits, participants will report on their symptoms and how they feel, receive blood tests and will have skin samples collected using skin tape. The feedback and data collected will help researchers track how well participants respond to the treatment.